Telitacicept Shows Promise as Alternative Treatment for IgA Nephropathy in Real-World Study
Key Insights
A retrospective study of 70 IgA nephropathy (search) patients demonstrated that telitacicept, a dual BLyS (search)/APRIL (search) inhibitor, achieved comparable efficacy to conventional immunosuppressive therapy with significantly fewer adverse events.
Patients treated with telitacicept showed rapid reduction in proteinuria and improved kidney function, with 24-hour proteinuria decreasing from 1.07 g to 0.26 g at 24 weeks in the overall telitacicept group.
The newly treated telitacicept subgroup achieved an 85% overall efficacy rate compared to 75% in the conventional immunosuppressive group, while experiencing lower adverse event rates (45% vs 75%).
IgA nephropathy (search) (IgAN), the most common primary glomerular disease worldwide and a leading cause of chronic kidney disease (search) in young adults, may have found a promising new treatment option. A retrospective case-control study published in a recent medical journal demonstrates that telitacicept, a dual-target receptor-antibody fusion protein, shows comparable efficacy to conventional immunosuppressive therapy while offering improved safety profiles.
The study, conducted at a single center, evaluated 70 IgAN patients across three treatment groups: 42 patients in the whole telitacicept group, 20 in the newly treated telitacicept subgroup (treatment-naive patients), and 28 in the conventional immunosuppressive group. Patients were followed for a median of 20-24 weeks, with all receiving treatment for at least 12 weeks.
Significant Proteinuria Reduction Across Treatment Groups
The primary endpoint of 24-hour proteinuria showed substantial improvements across all treatment groups. In the whole telitacicept group, proteinuria decreased from 1.07 g (IQR 0.66-1.99) to 0.26 g (IQR 0.17-0.59) at 24 weeks (P = 0.028). The newly treated telitacicept subgroup demonstrated even more pronounced results, with proteinuria dropping from 1.70 g (IQR 1.05-2.58) to 0.21 g (IQR 0.13-0.39) (P = 0.043). The conventional immunosuppressive group showed similar improvements, decreasing from 1.78 g (IQR 0.97-2.82) to 0.44 g (IQR 0.16-1.48) (P = 0.001).
Kidney function, as measured by estimated glomerular filtration rate (eGFR), also improved across treatment groups. The newly treated telitacicept subgroup showed a significant increase from 76.58 ± 30.26 ml/min/1.73 m² to 80.30 ± 26.76 ml/min/1.73 m² (P = 0.016), while the conventional immunosuppressive group improved from 72.73 ± 33.41 ml/min/1.73 m² to 84.08 ± 26.81 ml/min/1.73 m² (P = 0.011).
Comparable Efficacy Rates with Superior Safety Profile
Treatment efficacy rates showed no statistically significant differences between groups throughout the follow-up period. At the final assessment, the whole telitacicept group achieved a 66.7% overall efficacy rate, with 19 patients achieving partial remission and 9 achieving complete remission. The newly treated telitacicept subgroup demonstrated an 85% efficacy rate (12 partial remissions, 5 complete remissions), while the conventional immunosuppressive group achieved 75% efficacy (10 partial remissions, 11 complete remissions).
The safety profile strongly favored telitacicept treatment. The incidence of adverse events was significantly lower in the newly treated telitacicept subgroup compared to the conventional immunosuppressive group (45% vs 75%, P = 0.035). In the telitacicept groups, the most common adverse events were local skin reactions at injection sites (33.3% of patients), typically resolving within 2-3 days and decreasing in severity after 8 weeks of treatment.
Mechanism of Action and Clinical Implications
Telitacicept works by targeting both B lymphocyte stimulator (BLyS (search)) and A proliferation-inducing ligand (APRIL (search)), key factors in B cell activation and differentiation. This dual inhibition reduces the production of galactose-deficient IgA1 (Gd-IgA1 (search)), a main pathogenic factor in IgAN development. The drug is administered through weekly subcutaneous injections, with most patients in the study receiving 160 mg/week.
The study authors noted that patients treated with telitacicept experienced rapid treatment response, with significant reductions in 24-hour proteinuria observed as early as 4 weeks into treatment. This rapid onset, combined with the favorable safety profile, suggests telitacicept could serve as either a supplement to or alternative for conventional corticosteroid (search) therapy, potentially reducing steroid-associated side effects.
Study Limitations and Future Directions
The researchers acknowledged several limitations, including the single-center, retrospective design and relatively small sample size. Some patients in the telitacicept group also received concurrent corticosteroid (search) or immunosuppressive therapy, which may have reduced differences between treatment groups. Additionally, levels of Gd-IgA1 (search), a key biomarker in IgAN, were not assessed during treatment.
Telitacicept has previously shown therapeutic efficacy in systemic lupus erythematosus (search) and has completed phase 2 clinical trials for both primary Sjögren's syndrome (search) and IgAN. The current study represents the first real-world evidence of telitacicept's effectiveness in IgAN treatment, supporting its potential role in managing this challenging kidney disease.
The findings suggest that telitacicept may offer a valuable treatment option for IgAN patients, particularly those seeking alternatives to conventional immunosuppressive therapy or those who experience significant side effects from corticosteroids. However, larger, multicenter studies will be needed to confirm these promising results and establish optimal treatment protocols.